Patent 10940185 was granted and assigned to JCR Pharmaceuticals on March, 2021 by the United States Patent and Trademark Office.
[Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market.